Skip to main content
Evidence Snapshot

Complement C5

CHEMBL2364163 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T13:26:12Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL2364163
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Complement C5 as ChEMBL target CHEMBL2364163, mapped to UniProt P01031. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Complement C5
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL2364163
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P01031
Complement C5
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Complement C5 matters

As of 2026-09-13

Complement C5 is reviewed as Complement C5 (UniProt P01031); Complement C5 shows approved-linked disease relevance led by paroxysmal nocturnal hemoglobinuria. 5 more disease programs remain visible in the same review block.; 6 linked drugs keep this evidence frame grounded.; the current evidence base includes 4 approved drugs, 13 compounds, and 25 assays, with lead potency reaching pChEMBL 6.7.

Disease context
paroxysmal nocturnal hemoglobinuria

Complement C5 shows approved-linked disease relevance led by paroxysmal nocturnal hemoglobinuria. 5 more disease programs remain visible in the same review block. 6 linked drugs keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include CROVALIMAB, ECULIZUMAB, NOMACOPAN.

Start review with paroxysmal nocturnal hemoglobinuria because it currently carries approved-linked support. Linked drugs include CROVALIMAB, ECULIZUMAB, NOMACOPAN, POZELIMAB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Approved-linked 6 linked drugs
Activity base
Portfolio and assay base

ChEMBL currently tracks 4 approved drugs, 13 compounds, and 25 assays for this target. The dominant activity type is KD. CHEMBL2203296 is the current potency anchor at pChEMBL 6.7.

Use CHEMBL2203296 as the tractability anchor when discussing potency (pChEMBL 6.7).

Activity source · ChEMBL 36 via Core Engine
4 approved pChEMBL 6.7
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Complement C5 matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P01031, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why paroxysmal nocturnal hemoglobinuria is currently treated as approved-linked support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

13
Total Compounds
25
Total Assays
4
Approved Drugs
IC50: 4.0, KD: 8.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL2203296
 6.7 IC50 —
No preferred name
CHEMBL2204196
 6.4 IC50 —
No preferred name
CHEMBL15770
 6.2 Kd Approved
No preferred name
CHEMBL1316
 6.2 Kd Approved
No preferred name
CHEMBL4756677
 6.2 IC50 —

Approved Drugs

Structure Compound First Approval
RALOXIFENE
CHEMBL81
 1997
OXAPROZIN
CHEMBL1071
 1992
CARPROFEN
CHEMBL1316
 1987
SULINDAC
CHEMBL15770
 1978
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T13:26:12Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL2364163